Ghanbari Fahimeh, Hasani Samira, Aghili Zahra Sadat, Asgary Sedigheh
Applied Physiology Research Center Isfahan University of Medical Sciences Isfahan Iran.
Department of Plant and Animal Biology, Faculty of Biological Science and Technology University of Isfahan Isfahan Iran.
Food Sci Nutr. 2024 May 29;12(7):4569-4580. doi: 10.1002/fsn3.4142. eCollection 2024 Jul.
Cardiovascular diseases (CVDs) are a significant contributor to global morbidity and death, underscoring the importance of their prevention and treatment. The association between the development and progression of CVD and several risk factors has been extensively studied. Among these risk factors, the gut microbiota has garnered considerable attention of the scientific community during the last two decades. In particular, dysbiosis is directly associated with many risk factors of CVD in the host, such as diabetes. Prior research has demonstrated a robust correlation between dysbiosis and the development of CVD. Probiotics, prebiotics, and synbiotics are considered important regulators of microbiota imbalances as they increase the colonization of beneficial bacteria and thereby alter the gut microbiota. Although these beneficial effects of biotics are now widely recognized, new evidence has demonstrated that target therapy of the microbiota affects many other organs, including the heart, through a process commonly referred to as the gut-heart axis. In this review, we will discuss the potential benefits of probiotics, prebiotics, and synbiotics for the beneficial effects on cardiovascular disease by modulating gut microbiota.
心血管疾病（CVDs）是全球发病和死亡的重要原因，凸显了其预防和治疗的重要性。心血管疾病的发生和发展与多种风险因素之间的关联已得到广泛研究。在这些风险因素中，肠道微生物群在过去二十年中引起了科学界的广泛关注。特别是，生态失调与宿主中许多心血管疾病的风险因素直接相关，如糖尿病。先前的研究表明，生态失调与心血管疾病的发展之间存在密切关联。益生菌、益生元及合生元被认为是微生物群失衡的重要调节剂，因为它们能增加有益细菌的定植，从而改变肠道微生物群。尽管生物制剂的这些有益作用现已得到广泛认可，但新证据表明，微生物群的靶向治疗通过一个通常被称为肠-心轴的过程影响包括心脏在内的许多其他器官。在这篇综述中，我们将讨论益生菌、益生元及合生元通过调节肠道微生物群对心血管疾病产生有益影响的潜在益处。
